Pharmaceutical compositions and methods of blocking Bacillus anthracis
US10293040B1 · kind B1 · utility
0Cited by
6References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 24, 2015 |
| Grant date | May 21, 2019 |
| Priority date | — |
| Expiry date | Apr 24, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of Bacillus anthracis. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis attached through a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies which prevents Bacillus anthracis infection in an individual.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.